Thank you for all that you do!

Welcome to the second edition of Dermatology Times' LinkedIn newsletter! For our US-based readers, we hope you had a fantastic Labor Day weekend, taking time to relax and recharge. We also want to extend our heartfelt gratitude to all our readers for the vital work you're doing in dermatology. Your dedication and expertise continue to drive advancements and improve patient care, and we’re honored to support and share in your journey.

If you have questions, suggestions, or would like to contribute to a future edition, please contact us via LinkedIn or via email at [email protected].

??? Welcome, September

As we say goodbye to August and enter the month of September, reflect on top news stories and expert insights stories from the past 31 days — and explore Dermatology Times' customized September conference calendar, curated by your recommendations and insights.

?? Breaking News Brief

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) reported promising long-term results from the INTEGUMENT-OLE study, an extended trial of roflumilast cream 0.05% for treating mild to moderate atopic dermatitis in children aged 2 to 5. Arcutis plans to submit a supplemental New Drug Application to the FDA in early 2025 for approval of this treatment for younger children.

?? Research Roundup

Recent research into botulinum toxin A (BTA) as a treatment for depression has shown promising results. The study, involving 87 patients receiving BTA for facial wrinkles, found significant improvements in mood and self-confidence, though not in overall quality of life, which remained unchanged.

The AHEAD (Aiming High in Eczema/Atopic Dermatitis) recommendations, recently published in the Journal of the European Academy of Dermatology and Venereology, propose new treatment targets for atopic dermatitis based on a broad expert consensus. Developed from global patient insights and input from 87 dermatologists across 44 countries, these recommendations emphasize a patient-centered approach, setting both "moderate" and "optimal" targets to address symptoms and improve disease management.

?? Expert Insights

Christopher Bunick , MD, PhD, an associate professor of dermatology at 耶鲁大学 in New Haven, Connecticut, Dermatology Times’ 2024 Winter Editor in Chief, and an expert in immune-mediated and inflammatory skin disorders, in an article for Dermatology Times discussing the newly-published AHEAD recommendations:

"By setting higher treatment goals, the AHEAD recommendations emphasize the importance of achieving optimal targets for both skin clearance and itch relief. These targets are not merely aspirational; they are essential for improving patient outcomes."

?? Read more here.

?? Skin In The News

• A new NHS England report confirms that Skin Analytics' AI tool, DERM, performs well in skin cancer detection, with a 99.8% Negative Predictive Value, surpassing human dermatologists' 98.9%. DERM, tested on over 33,500 patients, can operate autonomously in the NHS if certified under UKCA IIa or CE III standards.
• Researchers at Rutgers University have discovered that a protein derived from parasitic worms could enhance skin wound healing. When applied to wounds in mice, this purified protein accelerated healing, improved skin regeneration, and reduced scarring.

?? Read more here.

Thank you for reading!